Interview with Dr. Ameet Sarpatwari on a legal case that could affect market entry of generic and biosimilar drugs. (12:14)Download A critical pathway that generics and biosimilars manufacturers have used to circumvent patent thickets has been “skinny labeling.” But a recent court ruling has placed this pathway under threat.
No takes yet. Share an insight, caveat, or question.
Tu et al. (2023) studied this question.